K
Karen M. Dwyer
Researcher at Deakin University
Publications - 122
Citations - 6210
Karen M. Dwyer is an academic researcher from Deakin University. The author has contributed to research in topics: Transplantation & Kidney disease. The author has an hindex of 29, co-authored 112 publications receiving 5435 citations. Previous affiliations of Karen M. Dwyer include University of Melbourne & Beth Israel Deaconess Medical Center.
Papers
More filters
Journal ArticleDOI
Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression
Silvia Deaglio,Karen M. Dwyer,Wenda Gao,David J. Friedman,Anny Usheva,Anna Erat,Jiang-Fan Chen,Keiichii Enjyoji,Joel Linden,Mohamed Oukka,Vijay K. Kuchroo,Terry B. Strom,Simon C. Robson +12 more
TL;DR: It is concluded that CD39 and CD73 are surface markers of T reg cells that impart a specific biochemical signature characterized by adenosine generation that has functional relevance for cellular immunoregulation.
Journal ArticleDOI
Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis
John Stagg,Upulie Divisekera,Nicole McLaughlin,Janelle Sharkey,Sandra Pommey,Sandra Pommey,Delphine Denoyer,Karen M. Dwyer,Karen M. Dwyer,Mark J. Smyth +9 more
TL;DR: This study identified tumor-derived CD73 as a mechanism of tumor immune escape and tumor metastasis, and established the proof of concept that targeted therapy against CD73 can trigger adaptive anti-tumor immunity and inhibit metastasis of breast cancer.
Journal ArticleDOI
Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors
Paul A. Beavis,Upulie Divisekera,Upulie Divisekera,Christophe Paget,Christophe Paget,Melvyn T. Chow,Melvyn T. Chow,Liza B John,Liza B John,Christel Devaud,Christel Devaud,Karen M. Dwyer,John Stagg,Mark J. Smyth,Phillip K. Darcy,Phillip K. Darcy +15 more
TL;DR: A2A/A2B receptor antagonists were effective in reducing the metastasis of tumors expressing CD73 endogenously and when CD73 was ectopically expressed, and strongly suggest that A2A or A2B antagonists may be useful for the treatment of metastatic disease.
Journal ArticleDOI
CD39 and control of cellular immune responses
TL;DR: The data indicate that CD39, together with CD73, efficiently distinguishes T regulatory cells (Treg) from other resting or activated T cells in mice (and humans) and serves as an integral component of the suppressive machinery of Treg, acting, at least in part, through the modulation of pericellular levels of adenosine.
Journal ArticleDOI
Expression of CD39 by Human Peripheral Blood CD4+CD25+ T Cells Denotes a Regulatory Memory Phenotype
Karen M. Dwyer,Dusan Hanidziar,Prabhakar Putheti,Prue Hill,Sandra Pommey,Jennifer L. McRae,Adam Winterhalter,Glen A. Doherty,Silvia Deaglio,Maria Koulmanda,Wenda Gao,Simon C. Robson,Terry B. Strom +12 more
TL;DR: The ectonucleotidase CD39 is a useful and dynamic lymphocytes surface marker that can be used to identify different peripheral blood T cell‐populations to allow tracking of these in health and disease, as in renal allograft rejection.